The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of somatic SWI/SNF alterations on the genomic landscape of pancreatic ductal adenocarcinoma and response to PARP and immune checkpoint inhibitor therapy.
 
Heng Tan
No Relationships to Disclose
 
Yasmine Baca
Employment - Caris Life Sciences
 
Joanne Xiu
Employment - Caris Life Sciences
 
Joanita Figueredo
Consulting or Advisory Role - UsinLife
 
Vaia Florou
No Relationships to Disclose
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
John Marshall
Employment - Caris Life Sciences; Indivumed
Leadership - 2curex
Honoraria - Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bayer/Onyx; Merck; Taiho Pharmaceutical
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics
Research Funding - D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Phillip Walker
Employment - Caris Life Sciences
 
Davendra Sohal
Honoraria - Foundation Medicine
Consulting or Advisory Role - Ability Pharma; AstraZeneca/MedImmune; Perthera
Speakers' Bureau - Genentech; Incyte
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); FibroGen (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst)
 
Igor A. Astsaturov
No Relationships to Disclose
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; Novartis; Pfizer; TriSalus Life Sciences
Research Funding - Ambrx (Inst); Amgen (Inst); Arcus Biosciences (Inst); BioMed Valley Discoveries (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
(OPTIONAL) Uncompensated Relationships - RenovoRx
 
Nkiruka Ezenwajiaku
No Relationships to Disclose
 
Jashodeep Datta
No Relationships to Disclose
 
Nipun B. Merchant
No Relationships to Disclose
 
Pearl H. Seo
No Relationships to Disclose
 
Jonathan C. Trent
Consulting or Advisory Role - Agios; Bayer; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; Epizyme; Janssen; Lilly; Novartis
 
Gilberto Lopes
Stock and Other Ownership Interests - Lucence Diagnostics; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics
 
Peter Joel Hosein
Research Funding - Agenus (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Eisai (Inst); NGM Biopharmaceuticals (Inst)